Literature DB >> 22703726

[Treatment duration of extra-pulmonary tuberculosis: 6 months or more? TB-INFO database analysis].

S Bouchikh1, J Stirnemann, V Prendki, R Porcher, H Kesthmand, A-S Morin, P Cruaud, S Rouaghe, D Farge, O Fain.   

Abstract

PURPOSE: The recommended duration of pulmonary tuberculosis therapy is 6 months. For extrapulmonary tuberculosis, treatment duration depends on tuberculosis involvement and HIV status. The objective of this study was to describe the main characteristics of a cohort of extrapulmonary tuberculosis patients, to compare patients with a 6-month treatment to those with more than a 6-month treatment, and to analyze the compliance of medical centres with recommended duration of treatment.
METHODS: A retrospective cohort study of 210 patients with extrapulmonary tuberculosis was carried from January 1999 to December 2006 in two hospitals in the north-east of Paris. These patients were treated with quadruple therapy during two months, followed by dual therapy during 4 months (n=77) or more (n=66). The characteristics of each group were compared by uni- and multivariate analysis. The primary endpoint was the rate of relapse or treatment failure at 24-month follow-up after treatment completion.
RESULTS: No relapse was observed after 24 months of follow-up after the end of treatment in the two groups. In univariate analysis, patients with lymph node tuberculosis were more often treated for 6 months than at other sites of tuberculosis (respectively 61% versus 40.9%; P=0.02); the decision of treatment duration was related to medical practices (79.2% treated 6 months in one hospital versus 20.7% in the other, P<0.001); patients living in private residence were more often treated during 6 months than patients living in residence (24.2% versus 10.3%, P=0.042). In multivariate analysis, only hospital (P=0.046), sex (P=0.007) and private residence were significantly different in each group.
CONCLUSION: A period of 6 months seems to be sufficient to treat extrapulmonary tuberculosis (except for neuromeningeal localization).
Copyright © 2012. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22703726     DOI: 10.1016/j.revmed.2012.05.008

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

1.  Polymorphisms of the BCL2 gene associated with susceptibility to tuberculosis.

Authors:  Juan He; Shengyuan Liu; Xujun Guo; Fan Zhang; Howard Eugene Takiff; Yashuang Zhao
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-09-30       Impact factor: 2.169

2.  Sternal tuberculosis.

Authors:  R Sachdeva; S Sachdeva; S Arora
Journal:  Ann Med Health Sci Res       Date:  2013-11

3.  Acute Hepatitis Induced by Intravesical BCG Therapy: A Rare but Serious Complication.

Authors:  Hakima Abid; Mouna Figuigui; Sidi Adil Ibrahimi; Mohamed El Abkari; Mohamed Mzyiene; Soufiane Ennaciri; Ouima Justin Ziba; Mohamed Jamal El Fassi; Layla Tahiri Elousrouti; Laila Chbani
Journal:  Case Reports Hepatol       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.